Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Zimhi (naloxone HCl Injection) is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, including fentanyl poisoning.
Lead Product(s): Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Zimhi
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: ZMI Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 20, 2024
Details:
Through the merger, Adamis will acquire DMK, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs including DPI-125, being studied as a potential novel treatment for opioid use disorder.
Lead Product(s): DPI-125
Therapeutic Area: Psychiatry/Psychology Product Name: DPI-125
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adamis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 25, 2023
Details:
Through the merger, Adamis will acquire DMK, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs including DPI-125, being studied as a potential novel treatment for OUD.
Lead Product(s): DPI-125
Therapeutic Area: Psychiatry/Psychology Product Name: DPI-125
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adamis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 27, 2023